Chemotherapy related nausea and vomiting
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis of acute myeloid leukemia (non-M3) according to WHO criteria 2016; Patients with prior chemotherapy and vomiting; The chemotherapy regimens were HAA IA medium-dose cytarabine and CLAG; Agree to participate in clinical studies and sign informed consent; No serious diseases such as brain liver kidney (serum creatinine= 1.5× upper limit of normal (ULN); or serum creatinine >1.5× ULN 24-hour creatinine clearance =50mL/min (using the Cockcroft-Gault formula); serum albumin= 3.0 g/dL; Serum total bilirubin = 1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5×ULN; Amylase = 1.5× ULN Lipase = 1.5×ULN; PT APTT AND INR = 1.5× ULN. Cardiac function indicators: ejection fraction (EF) > 50% pulmonary systolic blood pressure =50mmHg)
Exclusion criteria
Exclusion criteria: Those who are allergic to the study drug ingredient or its analogues; Those with poor skin condition; Those who have received autologous or allogeneic hematopoietic stem cell transplantation; The patient has nausea and vomiting due to neuropathic vomiting gastrointestinal obstruction and increased intracranial pressure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of nausea and vomiting; | — |
Secondary
| Measure | Time frame |
|---|---|
| The severity of nausea and vomiting;Time of nausea and vomiting; | — |
Countries
China
Contacts
Beijing University People's Hospital